dm+d

Unassigned

New Medicines

MultikineHead and neck (or upper airways tract) cancers, squamous cell - first-line

Information

Multikine
New molecular entity
CEL-SCI
CEL-SCI

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Immunotherapy providing both active and passive immune activity and is administered prior to any other cancer therapy including surgery or radiotherapy [1].
UK incidence of head and neck cancers is 12.6 per 100,000 people, but there are marked regional variations. Squamous cell carcinoma is the most common type affecting 90% of people. 30-50% will have recurrent disease within 5 years of initial treatment.
Head and neck (or upper airways tract) cancers, squamous cell - first-line
Peri-tumoural and peri-lymphatic